These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20164181)

  • 1. Critical role of the platelet-derived growth factor receptor (PDGFR) beta transmembrane domain in the TEL-PDGFRbeta cytosolic oncoprotein.
    Toffalini F; Hellberg C; Demoulin JB
    J Biol Chem; 2010 Apr; 285(16):12268-78. PubMed ID: 20164181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The fusion proteins TEL-PDGFRbeta and FIP1L1-PDGFRalpha escape ubiquitination and degradation.
    Toffalini F; Kallin A; Vandenberghe P; Pierre P; Michaux L; Cools J; Demoulin JB
    Haematologica; 2009 Aug; 94(8):1085-93. PubMed ID: 19644140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.
    Medves S; Noël LA; Montano-Almendras CP; Albu RI; Schoemans H; Constantinescu SN; Demoulin JB
    Haematologica; 2011 Oct; 96(10):1406-14. PubMed ID: 21685469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tel/PDGFRbeta induces stem cell differentiation via the Ras/ERK and STAT5 signaling pathways.
    Dobbin E; Graham C; Corrigan PM; Thomas KG; Freeburn RW; Wheadon H
    Exp Hematol; 2009 Jan; 37(1):111-121. PubMed ID: 19100521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
    Lacronique V; Boureux A; Monni R; Dumon S; Mauchauffé M; Mayeux P; Gouilleux F; Berger R; Gisselbrecht S; Ghysdael J; Bernard OA
    Blood; 2000 Mar; 95(6):2076-83. PubMed ID: 10706877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a role of NF-kappaB in the survival of hematopoietic cells mediated by interleukin 3 and the oncogenic TEL/platelet-derived growth factor receptor beta fusion protein.
    Besançon F; Atfi A; Gespach C; Cayre YE; Bourgeade MF
    Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8081-6. PubMed ID: 9653143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ARG tyrosine kinase activity is inhibited by STI571.
    Okuda K; Weisberg E; Gilliland DG; Griffin JD
    Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The leukemia-associated fusion protein Tel-platelet-derived growth factor receptor β (Tel-PdgfRβ) inhibits transcriptional repression of PTPN13 gene by interferon consensus sequence binding protein (Icsbp).
    Huang W; Hu L; Bei L; Hjort E; Eklund EA
    J Biol Chem; 2012 Mar; 287(11):8110-25. PubMed ID: 22262849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo.
    Yokota A; Hirai H; Shoji T; Maekawa T; Okuda K
    Leukemia; 2017 Dec; 31(12):2742-2751. PubMed ID: 28386107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A domain of TEL conserved in a subset of ETS proteins defines a specific oligomerization interface essential to the mitogenic properties of the TEL-PDGFR beta oncoprotein.
    Jousset C; Carron C; Boureux A; Quang CT; Oury C; Dusanter-Fourt I; Charon M; Levin J; Bernard O; Ghysdael J
    EMBO J; 1997 Jan; 16(1):69-82. PubMed ID: 9009269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
    Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
    Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. H4(D10S170), a gene frequently rearranged in papillary thyroid carcinoma, is fused to the platelet-derived growth factor receptor beta gene in atypical chronic myeloid leukemia with t(5;10)(q33;q22).
    Schwaller J; Anastasiadou E; Cain D; Kutok J; Wojiski S; Williams IR; LaStarza R; Crescenzi B; Sternberg DW; Andreasson P; Schiavo R; Siena S; Mecucci C; Gilliland DG
    Blood; 2001 Jun; 97(12):3910-8. PubMed ID: 11389034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Positive and negative regulatory roles of the WW-like domain in TEL-PDGFbetaR transformation.
    Chen J; Williams IR; Kutok JL; Duclos N; Anastasiadou E; Masters SC; Fu H; Gilliland DG
    Blood; 2004 Jul; 104(2):535-42. PubMed ID: 15054045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
    Stover EH; Chen J; Lee BH; Cools J; McDowell E; Adelsperger J; Cullen D; Coburn A; Moore SA; Okabe R; Fabbro D; Manley PW; Griffin JD; Gilliland DG
    Blood; 2005 Nov; 106(9):3206-13. PubMed ID: 16030188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic leukemia is a transforming protein that self-associates and activates PDGF beta R kinase-dependent signaling pathways.
    Carroll M; Tomasson MH; Barker GF; Golub TR; Gilliland DG
    Proc Natl Acad Sci U S A; 1996 Dec; 93(25):14845-50. PubMed ID: 8962143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.
    Sternberg DW; Tomasson MH; Carroll M; Curley DP; Barker G; Caprio M; Wilbanks A; Kazlauskas A; Gilliland DG
    Blood; 2001 Dec; 98(12):3390-7. PubMed ID: 11719379
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myc is essential for transformation by TEL/platelet-derived growth factor receptor beta (PDGFRbeta).
    Bourgeade MF; Défachelles AS; Cayre YE
    Blood; 1998 May; 91(9):3333-9. PubMed ID: 9558390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation.
    Tse KF; Mukherjee G; Small D
    Leukemia; 2000 Oct; 14(10):1766-76. PubMed ID: 11021752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transforming property of TEL-FGFR3 mediated through PI3-K in a T-cell lymphoma that subsequently progressed to AML.
    Maeda T; Yagasaki F; Ishikawa M; Takahashi N; Bessho M
    Blood; 2005 Mar; 105(5):2115-23. PubMed ID: 15514005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The MN1-TEL fusion protein, encoded by the translocation (12;22)(p13;q11) in myeloid leukemia, is a transcription factor with transforming activity.
    Buijs A; van Rompaey L; Molijn AC; Davis JN; Vertegaal AC; Potter MD; Adams C; van Baal S; Zwarthoff EC; Roussel MF; Grosveld GC
    Mol Cell Biol; 2000 Dec; 20(24):9281-93. PubMed ID: 11094079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.